Adagene hits preclinical milestone for Exelixis-partnered XB404 SAFEbody ADC, triggers $2 million payment
ADAG•Preclinical milestone triggers payment under Exelixis collaboration
Adagene hit a preclinical milestone for Exelixis-partnered XB404, a SAFEbody-masked ADC targeting ROR1/2-expressing tumors.
The milestone triggered a $2 million payment tied to XB404’s advancement under the collaboration.
Exelixis also selected candidates for another SAFEbody ADC program, triggering an additional payment not quantified.
The deal structure includes potential development and commercialization milestones, plus royalties on net sales of any resulting products.
